The initial analysis of the Know Your Tumor registry trial identified mutations in the HR-DDR (DNA damage repair) pathway in 25% of 820 patients with PDAC, subdivided into three groups: Group 1: BRCA1/2 and PALB2; Group 2: ATM/ATR/ATRX; and Group 3: BAP1, BARD1, BRIP1, CHEK1/2, RAD50/51/51B, or FANCA/C/D2/E/F/G/L [18]. Here, BRCA1 is linked to neoplasm.